{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:51:41Z","timestamp":1784551901764,"version":"3.55.0"},"reference-count":56,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>\n                    Safety differences between tenofovir alafenamide\/emtricitabine (TAF) and tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC)-formulated pre-exposure prophylaxis (PrEP) appear to have little clinical significance for most PrEP users. Furthermore, generic TDF-formulated PrEP is projected to decrease the price of PrEP. Thus, efforts to shift PrEP users to TAF-formulated PrEP should be considered in light of their potential to undermine efforts to scale-up PrEP nationally. Data are taken from\n                    <jats:italic toggle=\"yes\">Together 5,000,<\/jats:italic>\n                    a US national cohort study predominantly composed of cisgender gay and bisexual men. In 2019\u20132020, 5034 participants completed their 24-month assessment, which measured whether participants were switching from TDF (Truvada) to TAF (Descovy) for PrEP, and why. Of those reporting PrEP-use (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u20091009), 277 reported using Descovy for PrEP, and 223 provided a reason for switching to Descovy. A content analysis was used to code participant's reasons for switching. Over half (56%) of participants reported that their doctor recommended switching to Descovy. Without mentioning a provider recommendation, 32% of participants reported that perceived improved safety of Descovy, compared with Truvada, motivated their decision to change their prescription. Other factors cited included the smaller size of the pill and \u201cnewness\u201d of Descovy. Further, several participants mentioned negative advertising about Truvada as rationale for switching. Although scientific consensus supports the safety of both TDF\/FTC and TAF, our results suggest that current messaging through physicians and other sources have emphasized superior safety of TAF\u2014implying that TDF\/FTC may not be safe in the long term. Efforts to shift users onto TAF may undermine public perception of TDF-formulated PrEP.\n                  <\/jats:p>","DOI":"10.1089\/apc.2021.0033","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:19:33Z","timestamp":1628597973000},"page":"327-334","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Why Are Patients Switching from Tenofovir Disoproxil Fumarate\/Emtricitabine (Truvada) to Tenofovir Alafenamide\/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-340X","authenticated-orcid":false,"given":"Alexa B.","family":"D'Angelo","sequence":"first","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy, New York, New York, USA."},{"name":"CUNY Institute for Implementation Science in Population Health, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew A.","family":"Westmoreland","sequence":"additional","affiliation":[{"name":"CUNY Institute for Implementation Science in Population Health, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-7824","authenticated-orcid":false,"given":"Pedro B.","family":"Carneiro","sequence":"additional","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Johnson","sequence":"additional","affiliation":[{"name":"Treatment Action Group, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grov","sequence":"additional","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy, New York, New York, USA."},{"name":"CUNY Institute for Implementation Science in Population Health, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"CDC. US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20142017 Update: A Clinical Practice Guideline. Atlanta GA: U.S. Department of Health and Human Services 2018."},{"key":"e_1_3_4_3_2","unstructured":"American Academy of Pediatrics. HIV-1 PrEP drug can be part of strategy to prevent infection in at-risk adolescents. FDA Update News Articles Web site. 2018. Available at: https:\/\/www.fda.gov\/files\/science%20&%20research\/published\/HIV-PrEP-drug-can-be-part-of-strategy-to-prevent-infection-in-at-risk-adolescents.pdf (Last accessed June5 2021)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61235-5"},{"key":"e_1_3_4_5_2","unstructured":"U.S Food & Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. U.S. Food & Drug Administration. Press Announcements Web site. 2019. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic (Last accessed June24 2020)."},{"key":"e_1_3_4_6_2","unstructured":"Highleyman L . Descovy PrEP Works Equally Well May Be Safer for Kidneys and Bones. 2019. Available at: https:\/\/www.poz.com\/article\/descovy-prep-works-equally-may-safer-kidneys-bones (Last accessed June1 2020)."},{"key":"e_1_3_4_7_2","unstructured":"Artavia D . FDA Approves New Drug for PrEP Which May Offer Less Side Effects. Advocate. 2019. Available at: https:\/\/www.advocate.com\/health\/2019\/10\/03\/fda-approves-new-drug-prep-which-may-offer-less-side-effects (Last accessed July27 2020)."},{"key":"e_1_3_4_8_2","unstructured":"Hare C Coll J Ruane P et al. The phase 3 DISCOVER study: Daily F\/TAF or F\/TDF for HIV preexposure prophylaxis. In: Paper presented at: Conference on retroviruses and opportunistic infections Seattle Washington March 4\u20137 2019."},{"key":"e_1_3_4_9_2","unstructured":"Spinner C Brunetta J Shalit P et al. DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F\/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F\/TDF. In: Paper presented at: The International AIDS Conference Mexico City Mexico July 21\u201324 2019."},{"key":"e_1_3_4_10_2","unstructured":"Gilead Sciences. Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP\u2122 Compared With Truvada For PrEP\u00ae. 2019. Available at: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2019\/11\/gilead-presents-96-week-discover-trial-data-supporting-non-inferior-efficacy-and-key-safety-differences-of-descovy-for-prep-compared-with-truvada-for (Last accessed August1 2020)."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"e_1_3_4_12_2","unstructured":"Mallon P Brunet L R H et al. Weight gain before and after switch from TDF to TAF. In: Paper presented at: 23rd International AIDS Conference July 6\u201310 2020 2020. Virtual."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0236"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3337"},{"key":"e_1_3_4_15_2","unstructured":"AVAC: Global Advocacy for HIV Prevention . The Global PrEP Tracker AVAC. 2020. Available at: https:\/\/data.prepwatch.org (Last accessed January20 2021)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30312-5"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"e_1_3_4_18_2","unstructured":"Blackstock O . Barring cisgender women from the Descovy trials was a bad call STAT. 2019. Available at: https:\/\/www.statnews.com\/2019\/11\/25\/descovy-trials-excluded-cisgender-women-bad-call (Last accessed October2 2020)."},{"key":"e_1_3_4_19_2","unstructured":"Marill MC . The Dangers of Excluding Women From HIV Prevention Drug Tests . Wired. Science Web site. 2020. Available at: https:\/\/www.wired.com\/story\/the-dangers-of-excluding-women-from-hiv-prevention-drug-tests (Last accessed June24 2020)."},{"key":"e_1_3_4_20_2","unstructured":"Mandavilli A.F.D .A. Approves New H.I.V .-Prevention Drug but Not for Everyone . The New York Times. 2019. Available at: https:\/\/www.nytimes.com\/2019\/10\/04\/health\/fda-descovy-truvada-hiv.html (Last accessed August1 2020)."},{"key":"e_1_3_4_21_2","unstructured":"Walensky RP Paltiel DA. PrEP School: A field manual for the battle over HIV prevention drug pricing. In: Health Affairs Blog. Vol 8\/5\/20. healthaffaires.org: Health Affairs Bethesda Maryland 2019."},{"key":"e_1_3_4_22_2","unstructured":"Rosenberg J . Reactions are mixed as Gilead announces PrEP donations early launch of generic AJMC. 2020. Available at: https:\/\/www.ajmc.com (Last accessed November1 2020)."},{"key":"e_1_3_4_23_2","unstructured":"Conrad R Lutter R. Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices. fda.gov: FDA Center for Drug Evaluation and Research Silver Springs Maryland 2019."},{"key":"e_1_3_4_24_2","unstructured":"Drugs.com. Generic Descovy Availability. Generix Drugs Web site. 2020. Available at: https:\/\/www.drugs.com\/availability\/generic-descovy.html (Last accessed October4 2020)."},{"key":"e_1_3_4_25_2","unstructured":"Motley Crew Transcribing. Gilead Sciences (GILD) Q3. 2020. Earnings Call Transcript. 2020. Available at: https:\/\/www.fool.com\/earnings\/call-transcripts\/2020\/10\/29\/gilead-sciences-gild-q3-2020-earnings-call-transcr (Last accessed January10 2021)."},{"key":"e_1_3_4_26_2","unstructured":"Richards KT Hickey KJ Ward E. Drug Pricing and Pharmaceutical Patenting Practices. Congressional Research Service Washington DC 2020."},{"key":"e_1_3_4_27_2","unstructured":"Thomas JR . Patent \u201cevergreening\u201d: Issues in Innovation and Competition. 2009."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2323-1"},{"key":"e_1_3_4_29_2","unstructured":"European Commission. Pharmaceutical Sector Inquiry Final Report. In: EC Brussels 2009. Available at: https:\/\/ec.europa.eu\/competition\/sectors\/pharmaceuticals\/inquiry\/staff_working_paper_part1.pdf"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148939"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2736"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2019.05.003"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2196\/13715"},{"key":"e_1_3_4_34_2","first-page":"109019811989369","article-title":"Maximizing response rates to ads for free at-home HIV testing on a men-for-men geosocial sexual networking app: Lessons learned and implications for researchers and providers","author":"Grov C","year":"2020","unstructured":"Grov C, , Stief M, , Westmoreland DA, , MacCrate C, , Mirzayi C, , Nash D. Maximizing response rates to ads for free at-home HIV testing on a men-for-men geosocial sexual networking app: Lessons learned and implications for researchers and providers. Health Educ Behav, 2020:1090198119893692.","journal-title":"Health Educ Behav"},{"key":"e_1_3_4_35_2","unstructured":"Centers for Medicare & Medicaid Services . GILEAD SCIENCES INC. 2020. Available at: https:\/\/openpaymentsdata.cms.gov\/company\/100000000108 (Last accessed October4 2020)."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/15265161.2010.519226"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3043-8"},{"key":"e_1_3_4_38_2","unstructured":"Jones RG Ornstein C. Matching Industry Payments to Medicare Prescribing Patterns: An Analysis. New York NY: ProPublica 2016."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4189"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2016.11.010"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.2765"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02969-0"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4608"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.1210"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/0022243720972106"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16036"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440040088034"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-019-1735-3"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.18433\/J3KK6C"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0189"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3478"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02977-0"},{"key":"e_1_3_4_53_2","unstructured":"Dearment A . Gilead got a boost from a newly approved PrEP drug. Now a major insurer is dropping coverage. 2020. Available at: https:\/\/medcitynews.com\/2020\/08\/gilead-got-a-boost-from-a-newly-approved-prep-drug-now-a-major-insurer-is-dropping-coverage\/?rf=1"},{"key":"e_1_3_4_54_2","first-page":"65","article-title":"Standardized review and approval process for high-cost medication use promotes value-based care in a large Academic Medical System","volume":"11","author":"Durvasula R","year":"2018","unstructured":"Durvasula R, , Kelly J, , Schleyer A, , Anawalt BD, , Somani S, , Dellit TH. Standardized review and approval process for high-cost medication use promotes value-based care in a large Academic Medical System. Am Health Drug Benefits, 2018; 11:65\u201373.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_55_2","unstructured":"Aetna. Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan. 2020. Available at: www.aetna.com\/products\/rxnonmedicare\/data\/2016\/ID\/antiviral_hiv.html (Last accessed October4 2020)."},{"key":"e_1_3_4_56_2","unstructured":"Anthem Blue Cross Blue Shield. Updated coverage for HIV PrEP medications. 2020. Available at: https:\/\/providernews.anthem.com\/virginia\/article\/updated-coverage-for-hiv-prep-medications-2 (Last accessed October2 2020)."},{"key":"e_1_3_4_57_2","unstructured":"Cigna. HIV Products. 2020. Available at: https:\/\/cignaforhcp.cigna.com\/public\/content\/pdf\/coveragePolicies\/pharmacy\/p_0050_coveragepositioncriteria_hiv_aids.pdf?TSPD_101_R0=086fc07cafab2000df0933b36f2f27e6126766fdd42789c8e0bee5a1059d94f2a26808c86e22933c08a54a1f44143000228294ce1f6fa473509bbf17d02ea2bdb725e9cc4a2a2c6f5f7d3f50479b764cb31b20514b9cd7a98a423ec831233abf (Last accessed October2 2020)."}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/apc.2021.0033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2021.0033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2021.0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:04:15Z","timestamp":1777399455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/apc.2021.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1089\/apc.2021.0033"],"URL":"https:\/\/doi.org\/10.1089\/apc.2021.0033","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}